The majority of adjudicated events were coronary revascularisations (10.3% Repatha; 13.6% placebo), followed by myocardial infarction (2.1% Repatha; 2.9% placebo).

Sales of Repatha grew slowly since launch to reach around $150m in the second quarter of 2018, but have stayed pretty much static at that level since, with rising demand counterbalanced by price ...